ABS Stock Overview
Arterra Bioscience S.p.A., a research-based biotech company, engages in the research and development of various ingredients and natural solutions.
Price History & Performance
|Historical stock prices|
|Current Share Price||€2.90|
|52 Week High||€4.40|
|52 Week Low||€2.72|
|1 Month Change||1.40%|
|3 Month Change||-18.99%|
|1 Year Change||-6.75%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-14.99%|
Recent News & Updates
Estimating The Intrinsic Value Of Arterra Bioscience S.p.A. (BIT:ABS)
Today we will run through one way of estimating the intrinsic value of Arterra Bioscience S.p.A. ( BIT:ABS ) by taking...
|ABS||IT Biotechs||IT Market|
Return vs Industry: ABS exceeded the Italian Biotechs industry which returned -19.3% over the past year.
Return vs Market: ABS underperformed the Italian Market which returned 20.3% over the past year.
|ABS Average Weekly Movement||3.4%|
|Biotechs Industry Average Movement||7.5%|
|Market Average Movement||4.3%|
|10% most volatile stocks in IT Market||7.2%|
|10% least volatile stocks in IT Market||2.7%|
Stable Share Price: ABS is not significantly more volatile than the rest of Italian stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: ABS's weekly volatility (3%) has been stable over the past year.
About the Company
Arterra Bioscience S.p.A., a research-based biotech company, engages in the research and development of various ingredients and natural solutions. It develops technological platforms, extraction processes, and raw materials for use in the cosmetics, agriculture, and nutraceutics sectors. The company was founded in 2003 and is based in Naples, Italy.
Arterra Bioscience Fundamentals Summary
|ABS fundamental statistics|
Is ABS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ABS income statement (TTM)|
|Cost of Revenue||€1.36m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.18|
|Net Profit Margin||26.37%|
How did ABS perform over the long term?See historical performance and comparison
Is Arterra Bioscience undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ABS's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ABS's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ABS is good value based on its PE Ratio (16.5x) compared to the European Biotechs industry average (27.9x).
PE vs Market: ABS is good value based on its PE Ratio (16.5x) compared to the Italian market (19.1x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ABS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ABS is good value based on its PB Ratio (2.2x) compared to the XE Biotechs industry average (3.9x).
How is Arterra Bioscience forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Arterra Bioscience has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Arterra Bioscience performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ABS has high quality earnings.
Growing Profit Margin: ABS's current net profit margins (26.4%) are higher than last year (14.5%).
Past Earnings Growth Analysis
Earnings Trend: ABS's earnings have grown by 1.8% per year over the past 5 years.
Accelerating Growth: ABS's earnings growth over the past year (101.4%) exceeds its 5-year average (1.8% per year).
Earnings vs Industry: ABS earnings growth over the past year (101.4%) exceeded the Biotechs industry 50.7%.
Return on Equity
High ROE: ABS's Return on Equity (13.5%) is considered low.
How is Arterra Bioscience's financial position?
Financial Position Analysis
Short Term Liabilities: ABS's short term assets (€8.0M) exceed its short term liabilities (€664.5K).
Long Term Liabilities: ABS's short term assets (€8.0M) exceed its long term liabilities (€1.7M).
Debt to Equity History and Analysis
Debt Level: ABS has more cash than its total debt.
Reducing Debt: Insufficient data to determine if ABS's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: ABS's debt is well covered by operating cash flow (64.3%).
Interest Coverage: ABS's interest payments on its debt are well covered by EBIT (173.5x coverage).
What is Arterra Bioscience current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ABS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ABS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ABS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ABS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ABS's dividend in 3 years as they are not forecast to pay a notable one for the Italian market.
How experienced are the management team and are they aligned to shareholders interests?
Maria Colucci (61 yo)
Ms. Maria Gabriella Colucci serves as Chairman of the Board of Directors and Chief Executive Officer at Arterra Bioscience S.p.A.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Arterra Bioscience S.p.A.'s employee growth, exchange listings and data sources
- Name: Arterra Bioscience S.p.A.
- Ticker: ABS
- Exchange: BIT
- Founded: 2003
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: €19.067m
- Shares outstanding: 6.57m
- Website: https://www.arterrabio.it
Number of Employees
- Arterra Bioscience S.p.A.
- via Benedetto Brin, 69
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/19 21:24|
|End of Day Share Price||2022/01/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.